PubMed

Molecular targeted therapies for breast cancer treatment.

Schlotter CM, Vogt U, Allgayer H, Brandt B.

Breast Cancer Res. 2008;10(4):211. Epub 2008 Jul 24. Review.PMID: 18671839 [PubMed - indexed for MEDLINE]Related articlesFree article

Linkage between EGFR family receptors and nuclear factor kappaB (NF-kappaB) signaling in breast cancer.

Biswas DK, Iglehart JD.

J Cell Physiol. 2006 Dec;209(3):645-52. Review.PMID: 17001676 [PubMed - indexed for MEDLINE]Related articles

Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.

Corkery B, Crown J, Clynes M, O'Donovan N.

Ann Oncol. 2009 May;20(5):862-7. Epub 2009 Jan 15.PMID: 19150933 [PubMed - indexed for MEDLINE]Related articles

Interactions between estrogen and growth factor receptors in human breast cancers and the tumor-associated vasculature.

Pietras RJ.

Breast J. 2003 Sep-Oct;9(5):361-73. Review.PMID: 12968955 [PubMed - indexed for MEDLINE]Related articles

Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2.

Le XF, Mao W, Lu C, Thornton A, Heymach JV, Sood AK, Bast RC Jr.

Cell Cycle. 2008 Dec;7(23):3747-58. Epub 2008 Dec 16.PMID: 19029832 [PubMed - indexed for MEDLINE]Related articlesFree article

Molecular approach to breast cancer treatment.

Yarden Y, Baselga J, Miles D.

Semin Oncol. 2004 Oct;31(5 Suppl 10):6-13. Review.PMID: 15490369 [PubMed - indexed for MEDLINE]Related articles

The new generation of targeted therapies for breast cancer.

Syed S, Rowinsky E.

Oncology (Williston Park). 2003 Oct;17(10):1339-51; discussion 1352, 1355-6. Review.PMID: 14606361 [PubMed - indexed for MEDLINE]Related articles

Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer.

Marx C, Yau C, Banwait S, Zhou Y, Scott GK, Hann B, Park JW, Benz CC.

Mol Pharmacol. 2007 Jun;71(6):1525-34. Epub 2007 Mar 28.PMID: 17392524 [PubMed - indexed for MEDLINE]Related articlesFree article

Co-targeting insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer.

Chakraborty AK, Liang K, DiGiovanna MP.

Cancer Res. 2008 Mar 1;68(5):1538-45.PMID: 18316619 [PubMed - indexed for MEDLINE]Related articlesFree article

Molecular targets as therapeutic strategies in the management of breast cancer.

Sartor CI.

Semin Radiat Oncol. 2002 Oct;12(4):341-51. Review.PMID: 12382192 [PubMed - indexed for MEDLINE]Related articles

Biological therapy of breast cancer: recent clinical applications.

Baar J.

Curr Opin Investig Drugs. 2007 Dec;8(12):987-95.PMID: 18058569 [PubMed - indexed for MEDLINE]Related articles

OSU-A9, a potent indole-3-carbinol derivative, suppresses breast tumor growth by targeting the Akt-NF-kappaB pathway and stress response signaling.

Weng JR, Tsai CH, Omar HA, Sargeant AM, Wang D, Kulp SK, Shapiro CL, Chen CS.

Carcinogenesis. 2009 Oct;30(10):1702-9. Epub 2009 Aug 25.PMID: 19706645 [PubMed - indexed for MEDLINE]Related articles

Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer.

Bedard PL, de Azambuja E, Cardoso F.

Curr Cancer Drug Targets. 2009 Mar;9(2):148-62. Review.PMID: 19275756 [PubMed - indexed for MEDLINE]Related articles

Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.

Oliveras-Ferraros C, Vazquez-Martin A, López-Bonet E, Martín-Castillo B, Del Barco S, Brunet J, Menendez JA.

Int J Oncol. 2008 Dec;33(6):1165-76.PMID: 19020749 [PubMed - indexed for MEDLINE]Related articles

Multigene targeting of signal transduction pathways for the treatment of breast and prostate tumors: comparison between combination therapies employing bispecific oligonucleotides with either Rapamycin or Paclitaxel.

Rubenstein M, Tsui P, Guinan P.

Med Oncol. 2009;26(2):124-30. Epub 2008 Aug 7.PMID: 18686047 [PubMed - indexed for MEDLINE]Related articles

Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.

Sloss CM, Wang F, Liu R, Xia L, Houston M, Ljungman D, Palladino MA, Cusack JC Jr.

Clin Cancer Res. 2008 Aug 15;14(16):5116-23.PMID: 18698029 [PubMed - indexed for MEDLINE]Related articlesFree article

Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.

Creighton CJ, Massarweh S, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Shou J, Malorni L, Schiff R.

Cancer Res. 2008 Sep 15;68(18):7493-501.PMID: 18794137 [PubMed - indexed for MEDLINE]Related articlesFree article

The breast cancer cells response to chronic hypoxia involves the opposite regulation of NF-kB and estrogen receptor signaling.

Scherbakov AM, Lobanova YS, Shatskaya VA, Krasil'nikov MA.

Steroids. 2009 Jun;74(6):535-42. Epub 2009 Feb 21.PMID: 19428442 [PubMed - indexed for MEDLINE]Related articles

Optimizing outcomes in HER2-positive breast cancer: the molecular rationale.

Esteva FJ, Pusztai L.

Oncology (Williston Park). 2005 Nov;19(13 Suppl 5):5-16. Review.PMID: 19364051 [PubMed - indexed for MEDLINE]Related articles

Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.

Spector NL, Blackwell KL.

J Clin Oncol. 2009 Dec 1;27(34):5838-47. Epub 2009 Nov 2. Review.PMID: 19884552 [PubMed - indexed for MEDLINE]Related articles